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Abstract
Background: Congenital Cytomegalovirus (cCMV) is the most common cause of non-genetic hearing loss in
childhood. A newborn hearing screening program (NHSP) is currently running in Italy, but no universal cCMV nor
statewide hearing-targeted CMV screening programs have been implemented yet.
This observational monocentric study was aimed at estimating the rate of cCMV infections identified by CMV-DNA
analysis on Dried Blood Spots (DBS) samples in deaf children identified via NHSP in Northern Italy in the period
spanning from 2014 to 2018.
Methods: Children with a confirmed diagnosis of deafness and investigated for CMV-DNA by nucleic acid
extraction and in-house polymerase-chain reaction (PCR) on stored newborns screening cards (DBS-test) were
included in this study. Deafness was defined by a hearing threshold ≥20 decibel (dB HL) by Auditory Brainstem
Responses (ABR); all investigated DBS samples were collected within 3 days of life.
Results: Overall, 82 children were included (median age: 3.4 months; lower-upper quartiles: 2–5.3 months; males:
60.9%). Most of them (70.7%) presented bilateral hearing loss with a symmetrical pattern in 79.3% of the cases. ABR
thresholds were ≥ 70 dB HL (severe/profound deafness) in 46.5% of children. Among all tested children, 6.1%
resulted positive for cCMV. The rate of severe/profound deafness was statistically higher in children with cCMV
infection.
Conclusions: The addition of DBS-test to the NHSP allowed the identification, in their first months of life, of a
cCMV infection in 6.1% of children who had failed NHS. The introduction of a targeted CMV screening strategy
could help clinicians in the differential diagnosis and in the babies’ management. DBS samples can be considered a
“universal newborns biobank”: their storage site and duration should be the subject of political decision-making.
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Background
Cytomegalovirus is the leading cause of congenital infec-
tion (cCMV) affecting up to 0.8% of newborns in high
income countries [1]. A wide range of diseases, diag-
nosed either at birth or in childhood, has been corre-
lated to cCMV infection [1]; sensorineural hearing loss
is the most frequent permanent damage, occurring in 5–
40% of infected children, either symptomatic or not at
birth; as a matter of fact, cCMV is the most common
cause of non-genetic deafness in childhood [2]. An early
identification of infected children – ideally through a
universal neonatal screening - might allow a prompt
treatment, aimed at limiting the hearing loss progression
and possibly preventing the onset of cCMV-linked dam-
ages to the central nervous system in both symptomatic
and asymptomatic babies [3, 4].
According to the recent literature, the virological in-
vestigations for cCMV in infants failing their newborn
hearing screening program (NHSP) - which is performed
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in many countries- could overcome the absence of an
universal cCMV screening [3–6].
The diagnosis of cCMV infection can be achieved by
the examination of salivary/urinary samples collected
within the first 2–3 weeks of age as the results of NHSP
[3–6]; after this early period of life, it is possible to dis-
tinguish between congenital and acquired CMV infec-
tion just by examining the Dried Blood Spot (DBS)
samples on the ‘Guthrie’ cards that are universally col-
lected within three days from the birth. These Guthrie
cards are obtained in all newborns for the screening of
metabolic and genetic disorders and stored at the Re-
gional neonatal screening centre. Currently, a nation-
wide NHSP is in place, but neither a universal cCMV
nor a nationwide hearing-targeted CMV screening pro-
grams are ongoing in Italy.
This observational single-centre study was aimed at
estimating the rate of cCMV infection in children with
hearing loss identified via NHSP who were referred to a
Pediatric Audiology department in Lombardy (Northern
Italy) between 2014 and 2018.
cCMV infection was diagnosed through the virological
examination of DBS retrieved from the Regional neo-
natal screening centre.
Methods
Study design
This observational monocentric study was conducted in
Milan (Italy) between January 1st 2014 and December
31th 2018.
All children belonging to the 2014–2018 birth cohort
failing NHSP with transient-evoked optoacoustic emis-
sions (TEOAE) in one or both ears and that also under-
went Automated Auditory Brainstem Responses (A-
ABR) were eligible in the study. Children who showed
abnormal A-ABR recordings referred to the Audiology
Department of the “Fondazione IRCCS Ca’ Granda,
Ospedale Maggiore Policlinico” and with an informed
consent for retrieving and testing of DBS samples for
cCMV diagnosis were included in the study.
Data of included children encompassed gender, age,
age at diagnosis of hearing loss; information on hearing
loss severity, laterality and occurrence of unilateral hear-
ing loss were also collected at the enrollment.
The study population was categorized according to the
result of the ABR assessment:
i) with mild/moderate (20–70 dB HL) vs. severe/
profound (> 70 dB HL) hearing loss according to
ABR Wave threshold;
ii) affected by unilateral vs. bilateral hearing loss;
iii) presented with bilateral symmetric or asymmetric
hearing loss pattern. When hearing loss was
asymmetric, the worse ear was considered in the
hearing loss level allocation.
Ethics approval and consent to participate
Written informed consent was obtained from the legal
guardian of the children. The study was performed ac-
cording to the guidelines of the Institutional Review
Board on the use of biological specimens for scientific
purposes in keeping with Italian law (art.13 D. Lgs
196/2003). Since this was a retrospective study on the
results already available with us, it was not put up for
any clearance to an ethical committee. The data were
handled anonymously. The study accomplished the
Helsinki Declaration of 1975, rev. 2000.
ABR assessment
Clinical ABR determination of hearing threshold was
carried out at the Audiology Department at the “Fonda-
zione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico
di Milano”, a third level referral audiological centre in
Milan. In brief, babies were tested under spontaneous
sleep conditions in a soundproof and Faradized room;
Ag-AgCl electrodes were stuck in a conventional A1-
A2-Cz-Fpz configuration and connected to the Naviga-
tor Pro (Natus Bio-logic, California, USA) recording
apparatus.
The stimuli were biphasic clicks delivered monaurally
via a TDH-39 (Smart Diagnostic Devices, Minnesota,
USA) transducer at a repetition rate of 11pps with 10 dB
HL steps of decreasing in intensity until the wave V be-
came indistinguishable from the baseline. Responses to
2000 clicks were averaged. For each recording condition
the trials were repeated at least twice.
When a diagnosis of deafness was confirmed for a
child, an informed consent for retrieving and testing of
DBS samples for cCMV was obtained from parents.
CMV-DBS test
Between January 1st 2014 and December 31th 2018, DBS
samples collected from children with a diagnosis of deaf-
ness were retrieved from the regional neonatal screening
centre and tested for CMV at the Virological Laborator-
ies of the Department of Biomedical Sciences for Health,
University of Milan.
DBS samples were processed by two separate in-house
steps consisting of DNA extraction from the DBS sam-
ples by a heat-extraction-method, followed by amplifica-
tion of a fragment of the CMV genome using a nested-
PCR. Briefly, 3 × 3 mm punches (1 punch/tube; area of
single punch: 7.1 mm2; overall area of punches: 21.3
mm2) of DBS were collected from each ‘Guthrie’ card.
The punches were initially incubated in 35 μL of Mini-
mum Essential Medium plus Earle’s solution (EuroClone
SpA, Milano, Italy) overnight at 4 °C, followed by 60 min
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at 56 °C and then heated for 7 min at 100 °C. After 3 min
of centrifugation (10,000 rpm) the supernatants were
frozen for 1 h at −80 °C. An house-keeping gene was
amplified with a PCR designed to recognise human
beta-2 microglobulin, as previously described [7],
followed by a nested-PCR designed to amplify the
CMV UL55 gene [8]. The first round-PCR conditions
consisted of 1 cycle of 2 min at 95 °C, followed by 35
cycles of 30 s at 95 °C, 30 s at 58 °C, 30 s at 72 °C and
a final cycle of 5 min at 72 °C. The second round-
PCR conditions consisted of 1 cycle of 15 min at
95 °C, followed by 30 cycles of 30 s at 95 °C, 30 s at
50 °C, 30 s at 72 °C and a final cycle of 5 min at 72 °C
[8]. The lower limit of detection of the CMV-DBS
test is 400 CMV-DNA copies/mL.
Data analysis
The statistical analysis was performed using the Open
Source Epidemiologic Statistics for Public Health (Open-
Epi, Georgia, USA) version 3.03. The frequencies were
expressed as a crude proportion with a corresponding
95% confidential interval (CI), assuming a normal distri-
bution. Proportions between groups were compared
using the Mid-P exact test based on binomial distribu-
tion. Lower (Q1) and upper (Q3) quartiles were com-
puted. The risk of infection was expressed as the
number of individuals with a laboratory-confirmed
cCMV infection out of the total number of children with
hearing loss and a specific characteristic. Odd Ratio
(OR) and exact CI were computed. The two-sample t-
test and the Fisher’s exact test were used for continu-
ous and categorical variables, respectively. P values of
<.05 were considered to be statistically significant
(two-tailed test).
Results
During the 4 years recruitment period, 89 children failed
NHSP. For 82 of them (92.1%) the DBS samples were
available and included in the study. For 7 children DBS
samples were not retrieved because stored out of our re-
gional screening center or the informed consent was not
obtained thus were excluded from the data analysis.
For children included in the study, the median age for
ABR diagnosis after NHSP was 3.4 months (Q1: 2
months - Q3: 5.3 months). Most hearing loss diagnoses
(66/82; 80.5%) were achieved before the age of 6 months
and more than half of them (37/66; 56%) were obtained
before the age of 3 months. No differences in distribu-
tion by gender were observed: 50/82 (60.9%) were males
(p-value =0.08).
Seventy-seven percent of children (58/82; p-value
<.0001) presented with bilateral hearing loss that showed
a symmetrical pattern in 79.3% (46/58; 95% CI: 67.2–
87.7%; p-value <.0001) of cases. ABR threshold resulted
≥70 dB HL (severe/profound deafness) in 46.5% of the
children (38/82; 95% CI: 35.9–57.0; p-value =0.90).
Twenty-eight out of 82 children (34.1%; 95% CI: 24.8–
44.9%), required hearing aids.
The timing of the DBS samples’s retrieval and examin-
ation was marked by the timing of hearing diagnoses by
ABR. According to the virological investigation, 6.1% (5/
82; 95% CI: 2.6–13.5%) of DBS samples tested positive
for cCMV. The rate of children with severe/profound
deafness was significantly higher in those with cCMV in-
fection than in the remaining others: 100% vs 42.9% re-
spectively (p-value =0.018).
No difference between unilateral and bilateral hearing
loss (OR = 0.6; 95% CI: 0.08–5.2) and between symmet-
rical vs. asymmetrical hearing loss (OR = 0.6; 95% CI:
0.07–5.1) was evidenced comparing cCMV-positive and
cCMV-negative children.
Discussion
cCMV infection is a very serious public health issue, ei-
ther for its significant prevalence - up to 1% of all new-
borns - and for the severe and permanent sensorial and
neurological impairments it can cause [1]; among these,
hearing loss has the highest impact on the children’s
health, endangering their neurological, cognitive and be-
havioural development [2].
Hearing loss due to cCMV infection can be already de-
tected at birth, but a diagnosis is commonly established
later on, usually during the first years of life, owing to
the often delayed and progressive manifestation of the
neurological damage [2]. The best preventive strategy
would be the implementation of a universal neonatal
cCMV screening, being able to identify the totality of
cCMV-positive children. It would also enable an earlier
identification and correction of the main cause of hear-
ing loss with post-natal onset [5]. If, for any reason, a
neonatal cCMV screening is not feasible on a large scale,
at least a hearing-targeted cCMV screening should be
set up: it would allow the early identification of children
with cCMV-related hearing loss, although it would miss
delayed hearing losses or other cCMV-related disease [3,
4, 9]. The following benefits from hearing-targeted CMV
screening can be underlined; i) it would provide an ac-
curate assessment of the aetiology of childhood deafness,
helping physicians in children’s management and fol-
low-up; ii) it would allow an adequate counselling
and support to parents; iii) it would help predicting
whether another child might be born with hearing-
linked damages and, finally, iv) it could alert clini-
cians on the possible neurological and behavioural
complications. In addition, hearing-targeted cCMV
screening has demonstrated to be cost-effective for
the public health perspective and feasible for health-
care facilities in highly resourced settings [9, 10].
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At present, no universal- or hearing-targeted cCMV
screening is operating in Italy; Tuscany is the only re-
gion where all the newborns who failed the first level
screening with TEOAE are tested for urinary CMV DNA
within the 15th day after birth [11].
In our observational single-institution study, hearing
loss has been diagnosed via NHSP, whereas the ascertain-
ment of the cCMV nature of the damage was possible
through the examination of DBS samples collected at
birth, whose usefulness for cCMV diagnosis has been
widely demonstrated [10, 12–15]. In agreement with Bou-
dewyns et al. [12], the investigated children were on aver-
age 3.4 months old, far beyond the age (2–3 weeks) at
which a congenital infection can be diagnosed through the
classical analysis of urinary/salivary samples, as it is
planned in a standard cCMV hearing targeted screening.
DBS are the only samples routinely collected at birth
and stored, for a short or extended time depending upon
each country policies; thus, they represent a ‘universal
newborns biobank’ that offers the best chance to get a
retrospective cCMV diagnosis.
Even though the sensitivity of DBS testing can be
highly variable since it is strongly affected by the blood
component release from ‘Guthrie’ Card and by the nu-
cleic acid extraction methodology applied for [12–15],
the outcomes of the present study are in agreement with
the literature: cCMV infection was identified in 6.1% of
children, similarly to other reports in which the rate of
cCMV in children failing NHSP ranged between 5 and
8% [3, 4, 12]. The workflow of an hearing-targeted
cCMV screenings can also been realized by CMV PCR
testing on saliva and/or urine [3]; however, in this set-
ting, we absolutely needed to have the results of audio-
logical examination (TEOAE and ABR) before children
were 21 days old days and prior the hospital discharge of
the children in order to collect saliva and urine that -
unlike in the case of DBS - are not routinely sampling at
birth [3].
As far as the correlation of cCMV infection to severity
and laterality of hearing loss is concerned [13, 16], in
our series the percentage of severe/profound deafness
was statistically higher (p = 0.018) in children with
cCMV infection (100%) than in the rest of the group
(42.9%), making the risk to develop a severe/profound
deafness higher in children with cCMV infection. This
implies that likelihood of developing severe/profound
deafness is much higher in the event of cCMV, confirm-
ing the trend observed by other researches [13, 16].
A review from Grosse et al. [2] showed that the bila-
terality of deafness caused by cCMV is unpredictable,
ranging from 25 to 80%. In our study, bilateral hearing
loss developed in 71% of cCMV-positive children; no
statistical difference between the occurrence of unilateral
vs. bilateral hearing loss was evidenced.
Regardless of hearing loss aetiology, children language
outcomes depend on time of deafness’ recognition and
can be improved with a diagnosis within 6 months of
age [3, 4, 6, 17].
Conclusions
In conclusion, using the DBS-test based on NHSP
allowed to identify cCMV infection in 6.1% of children
failing NHSP in their first months of life, and to
recognize that the risk to develop severe/profound deaf-
ness was higher in the event of cCMV. We are con-
vinced that it is time to move toward a hearing-targeted
CMV screening strategy, that would provide undoubted
benefits for patients and clinicians [6, 16]. Moreover,
hearing-targeted cCMV screening yields relevant impli-
cations from the public health perspectives. Besides the
economic savings expected with the reduction of ex-
penses for social support when CMV damages are pre-
vented or treated earlier [9], the early recognition of
cCMV can drive further public health and social initia-
tives; all these, can improve the community outreach
and the health workers in-depth knowledge about cCMV
infection and its prevention.
Finally, DBS samples can be considered a “universal
newborns biobank”: the site and the duration of their
storage should be addressed in political decision-making.
The alternative of leaving the DBS samples to parents
could overcome the fear of loss of privacy and the costs
for a correct samples storage.
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